CVS Stock CVS Health Corporation
US · NYSELast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Low valuation and potential insurance-margin stabilization offer substantial turnaround upside.
Future value: $115.48 (+23.55%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Potential margin recovery in managed care remains the key catalyst.
- ▸Above 50-day MA (+2.03%)
- ▸Above 200-day MA — long-term uptrend
- ▸~24% upside to price target
Is CVS a buy right now?
Trend: CVS is trading above the 50-day average (+1.10%), RSI 55 — neutral momentum, with a 3-month return of -15.37%.
Valuation & quality: CVS Health Corporation trades on a trailing P/E of 24.4, forward P/E 10.8, PEG 0.22, price-to-book 1.48; fundamentals show net margin 1.2%, return on equity 6.2%, revenue growth 7.1% year on year.
Analyst consensus: 25 analysts have a mean 12-month price target of $115.48 (+24.8% vs the last close; range $103.00 – $145.00), consensus rating “strong buy”.
Income: trailing dividend yield 2.85%.
Our screen: BUY (score 3) — Low valuation and potential insurance-margin stabilization offer substantial turnaround upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.10% | +16.00% | +9.20% | +13.70% | +0.90% | -10.10% | -8.80% | +8.00% |
Fundamentals
Analyst price target
Technical signals
About CVS Health Corporation
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare…
Sector: Healthcare · Industry: Healthcare Plans · United States · 219,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.